Molecular and prognostic classification of advanced melanoma: A multi-marker microcontamination assay of peripheral blood stem cells

Melanoma Research

Volumn 10, Issue 4, 2000, Pages 355-362

  Schrader, A J ^a   Probst Kepper, M ^a   Grosse, J ^b   Kunter, U ^a   Schenk, F ^a   Franzke, A ^b   Atzpodien, J ^b   Buer, J ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Malignant melanoma; Microcontamination; Molecular tumour cell characterization; Peripheral blood stem cells; Prognosis

Indexed keywords

TYROSINASE RELATED PROTEIN 1; TYROSINASE RELATED PROTEIN 2;

ADULT; ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL;

ADULT; ANTIGENS, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE I; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MELANOMA; MELANOMA, AMELANOTIC; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM PROTEINS; PREGNANCY PROTEINS; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0033818652     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200008000-00007     Document Type: Article

References (29)

1. Incidence, risk factors and prevention of melanoma
2. Combined chemoimmunotherapy in metastatic melanoma - Is there a need for the double?
3. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction
4. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse
5. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase polymerase chain reaction
6. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction
7. Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology
8. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma
9. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma
10. Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma
11. Lymph node micrometastases of cutaneous melanoma: Increased sensitivity of molecular diagnosis in comparison to immunohistochemistry
12. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay
13. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanotic lesions
14. Melonoma-associated antigens as messenger RNA detection markers for melanoma
15. Sequential chemoimmunotherapy in the treatment of metastatic melanoma
16. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and inferferon alpha 2a
17. Expression of MAGE genes in primary and metastatic cutaneous melanoma
18. DNA sequencing with chain-terminating inhibitors
19. Melanocyte lineage specific antigens recognised by monoclonal antibodies NKI-beteb, HMB-50 and HMB-45 are encoded by a single cDNA
20. A monoclonal antibody specific for cells of the melanocyte lineage
21. A new B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t(14;18) and t(4;11) chromosomal dislocations
22. Nonparametric estimation from incomplete observations
23. Detection and clinical importance of micro-metastatic disease
24. New prognostic factors in melanoma: mRNA tumour markers
25. Incomplete expression of the tyrosinase gene family (tyrosinase, TRP-1, and TRP-2) in human malignant melanoma cells in vitro
26. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
27. Expression of MAGE genes in renal cell carcinoma
28. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based immunotherapies?
29. Cutaneous melanoma